N/A
Completed N=32
Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Rash
Source: ClinicalTrials.gov NCT00709878 ↗
Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Sep 2010
Primary outcomePrimary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. — 1; 1; 0; 2 Total number of cases
Summary
The purpose of this study is to characterize the microscopic findings of skin rash associated with the use of chemotherapeutic anticancer agents known as epidermal growth factor inhibitors (EGFRIs).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and Panitumumab. |
1; 1; 0; 2; 1; 2 | — |
Eligibility Criteria
Inclusion Criteria
- Patients treated with lapatinib who developed skin toxicities and were biopsied.
- Patients treated with erlotinib, cetuximab, or panitumumab who have been biopsied for skin rash.
Exclusion Criteria
- Patients who do not fit above criteria.
Data sourced from ClinicalTrials.gov (NCT00709878). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.